Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIK1 | P39086 | 9/20 | 0.72 |
| ▸ | MEN1 | O00255 | 2/20 | 0.68 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.68 |
| ▸ | RAB9A | P51151 | 1/20 | 0.68 |
| ▸ | GFER | P55789 | 1/20 | 0.64 |
| ▸ | TRPM4 | Q8TD43 | 1/20 | 0.63 |
| ▸ | TP53 | P04637 | 1/20 | 0.57 |
| ▸ | GRIK2 | Q13002 | 1/20 | 0.56 |
| ▸ | SERPINE1 | P05121 | 1/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.55 |
| ▸ | SLC16A3 | O15427 | 1/20 | 0.54 |
| ▸ | CNR1 | P21554 | 1/20 | 0.54 |
| ▸ | CNR2 | P34972 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1308410 | 0.89 | GFER (0.76) | GRIK1MEN1KMT2ARAB9AGFER | |
| SCHEMBL1955845 | 0.86 | GFER (0.78) | GRIK1MEN1KMT2ARAB9AGFER | |
| SCHEMBL9281809 | 0.84 | GFER (0.76) | MEN1KMT2ARAB9AGFERKDM4E | |
| SCHEMBL5475049 | 0.84 | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 (0.74) | GRIK1MEN1KMT2ARAB9AGFER | |
| SCHEMBL1308314 | 0.83 | GRIK1 (0.69) | GRIK1MEN1KMT2ATRPM4KDM4E | |
| SCHEMBL11690219 | 0.81 | GRIK1 (0.76) | GRIK1MEN1KMT2ATRPM4GRIK2 | |
| SCHEMBL1309907 | 0.81 | GRIK1 (0.71) | GRIK1MEN1KMT2ARAB9ATP53 | |
| SCHEMBL1310106 | 0.80 | GRIK1 (0.74) | GRIK1MEN1KMT2ASERPINE1 | |
| SCHEMBL1307456 | 0.78 | GRIK1 (0.67) | GRIK1MEN1KMT2AGRIK2SERPINE1 | |
| SCHEMBL1308769 | 0.78 | PPARG (0.69) | GRIK1MEN1KMT2ARAB9AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090042918-A1 | Pyridopyrimidinone Inhibitors of PIM-1 and/or PIM-3 | EXELIXIS, INC. (US) | 2009-02-12 | — | — | US | claimed |
| US-8053454-B2 | Pyridopyrimidinone inhibitors of PIM-1 and/or PIM-3 | EXELIXIS, INC. (US) | 2011-11-08 | — | — | US | disclosed |
| US-20090042918-A1 | Pyridopyrimidinone Inhibitors of PIM-1 and/or PIM-3 | EXELIXIS, INC. (US) | 2009-02-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090042918-A1 | Pyridopyrimidinone Inhibitors of PIM-1 and/or PIM-3 | PIM1, PIM3, PIM2 | GRIK1 2986/4885MEN1 2312/4885KMT2A 1570/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.